OI Research Update: Ultragenyx Orbit and Cosmic Phase 3 Study Enrollment is Complete

We are pleased to share exciting news from our partners at Ultragenyx. They have completed enrollment for their Phase 2/3 Orbit and Phase 3 Cosmic studies. These studies evaluate setrusumab (UX143) in both pediatric and young adult patients with osteogenesis imperfecta (OI).

“We would like to thank the OI community for its support, trust and participation as we complete this important step in the advancement of the setrusumab program,” said Eric Crombez, M.D., chief medical officer at Ultragenyx.

For more information about the studies and what this development means for our community, please visit https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-completion-enrollment-phase-3-orbit-and